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imaging (MRI) demonstrated a 12 × 10 cmmultilocular cystic mass con-
taining several solid portions with multiple disseminations and ascites in
her pelvis. Computed tomography (CT) did not detect any sign of distant
metastasis or lymphadenopathy. Preoperative CA125was 88.6 U/ml (nor-
mal b35 U/ml), and alpha-fetoprotein (AFP) was not evaluated at this
point. She underwent total abdominal hysterectomy with bilateral
salpingo-oophorectomy, pelvic lymphadenectomy, partial omentectomy,
appendectomy, and partial peritonectomy. The ascetic ﬂuid (3030 ml)
was hemorrhagic and positive by cytologic examination. The right ovary
was replaced by a tumor, 12 × 7 cm in diameter with a smooth surface.Introduction
Ovarian yolk sac tumor (YST) is characterized by endodermal differ-
entiation, and represents approximately 20% of malignant germ cell
neoplasms. The age distribution of patients reported with YST ranges
from 16 months to 46 years, but most patients are under 30 years of
age (Talerman and Vang, 2011). YST is often found admixed with
other types of germ cell neoplasm, but YST associated with epithelial
ovarian carcinoma is extremely rare (Talerman and Vang, 2011). Unlike
pure YST, YST associated with epithelial ovarian carcinoma is reported
in elderly patients, and has a poor response to chemotherapy. Here we
describe a case of YST associated with endometrioid adenocarcinoma
in a postmenopausal woman. Our patient responded favorably to treat-
ment with Docetaxel and Carboplatin combination chemotherapy, and
has survivedwithout evidence of relapse for 48 months postoperatively
including a long term follow-up program. To the best of our knowledge,
this is the ﬁrst report of YST associated with endometrioid adenocarci-
noma with longterm (N48 months) successful therapy treatment,
according to a Medline search of English publications.
Case report
A56-year-oldpostmenopausalwomanpresentedwith abdominal full-
ness and a rapid weight gain of 5 kg in a week. She had an approximately
10 cmpelvicmass uponphysical examination, and a left adnexalmasswas.
c. This is an open access article underThe cyst contained brown serousﬂuid and a3 cmsolid tumorwith necrot-
ic tissue. The left ovary was normal, but uterine serosa, omentum, and
mesentery had multiple nodules with easy bleeding. There were also
many peritoneal disseminated tumors within the pelvis and the abdomi-
nal cavity, and under the diaphragm. We could not resect completely,
and all mesentery nodules and most tumors under the diaphragm were
residual. The reduction rate was estimated to be about 60% of the whole
tumors. The histopathological examination demonstrated a yolk sac
tumorwith endometrioid adenocarcinoma (G3) of the ovary. The diagno-
sis was staged as pT3cN0M0. We measured a preoperative AFP serum
level using reserved serum, of 374,700 ng/ml (normal b20 ng/ml). A com-
bination chemotherapy including Bleomycin, Etoposide, and Cisplatin
(BEP chemotherapy) to target the YST component was initiated. However
there was no response after two courses. CT showed the appearance of
liver metastasis and an increase of residual tumors. Docetaxel and
Carboplatin combination chemotherapy (DC chemotherapy) was admin-
istered. The high AFP serum level declined rapidly after starting the DC
chemotherapy, falling within the normal range after four courses (Fig. 1).
Furthermore, most of the liver metastasis and multiple residual tumors
disappeared after six courses (Fig. 2). Our patient's follow-up consisted
of monthly AFP serum level tests and CT images every three months.Histopathological ﬁndings
There were two different types of histological components. The ﬁrst
element was YST, composed of mainly reticular or papillary patterns
(Fig. 3A-1). The second one was poorly differentiated endometrioid
adenocarcinoma, which showed solid growth and complex glandular
patterns with marked nuclear pleomorphism and mitotic activity
(Fig. 3B-1). Furthermore, there were some foci of endometriosis com-
posed of an epithelial lining and endometrial stromal cells.the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. SerumAFP levels. The high serum AFP level declined rapidly after DC chemotherapy.
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Immunohistochemical studies demonstrated that the YST compo-
nent was positive for AFP, but negative for CK7 and EMA (Fig. 3A-2, 3,
4). In contrast, the endometrioid adenocarcinoma component was
negative for AFP, but positive for CK7 and EMA (Fig. 3B-2, 3, 4). Immu-
nohistochemical ﬁndings conﬁrmed that this tumor had both YST and
endometrioid adenocarcinoma elements.
Discussion
In 1987, Rutgers et al. reported the case of “ovarian YST arising from
an endometrioid carcinoma” for the ﬁrst time (Rutgers et al., 1987);
since then thirteen cases of YST with endometrioid adenocarcinoma
have been reported (Rutgers et al., 1987; Nogales et al., 1996; Kamoi
et al., 2002; Hong et al., 2010). Nogales et al. characterized the features
of this rare tumor as follows: (1) Most of these tumors occur in
perimenopausal woman. (2) Endometriosis often coexists with these
tumors as a precursor lesion. (3) Both the YST component and theFig. 2. Change of residual lesions by DC chemotherapy. Most of the liver metastasis aendometrioid component show typical histological patterns, respec-
tively. (4) Immunohistochemical studies show that the YST component
is positive for AFP, but the endometrioid component is negative for AFP
(Nogales et al., 1996). The presented case coincided well with this deﬁ-
nition. To summarize the previous thirteen cases, this tumor often had
aggressive behavior and poor response to chemotherapy. Nine patients
died within an average of 7 months (3–14 months) from the diagnosis,
and the other four are disease-free at an average follow-up time of
16 months (12–21 months). Their prognosis had no correlation with
the stage or the histologic grade of the endometrioid component.
According to the past literature, more than 38% of epithelial ovarian
carcinoma secrete detectable amounts of AFP (Bose and Mukherjea,
1993), and 6.5% show histochemical evidence of AFP secretion in
individual cells (Casper et al., 1984). Therefore, it is important not
only to determine each different histological type, but also to distin-
guish immunohistochemically between the YST component and the
endometrioid component. Ramalingam et al. reported on the use of
CK7 and EMA in differentiating ovarian YST from endometrioid adeno-
carcinoma (Ramalingam et al., 2004). CK7 and EMA are negative in
YST, but positive in endometrioid adenocarcinoma,while AFP is positive
in YST, but negative in endometrioid adenocarcinoma. We also could
distinguish this tumor from an endometrioid-like variant of YST that
was proposed as a distinctive subtype of YST by Clement et al. (1987).
They described the diagnostic features of YST that occur in young
patients and immunohistochemical stains for AFP showed a positive
reaction in the endometrioid-like foci as well as typical YST areas.
Although some theories have been proposed (Rutgers et al., 1987;
Nogales et al., 1996; Kamoi et al., 2002; Hong et al., 2010), the biological
behavior of this rare tumor is uncertain. This tumor often occurs in peri-
menopausal women and has poor response to chemotherapy. Therefore,
the clinical characteristics are thought to resemble endometrioid adeno-
carcinoma rather than YST. On the other hand, the prognosis has no cor-
relation with the stage or the histologic grade of the endometrioid
component, and the YST component has a tendency to be seen in meta-
static tumors and recurrent lesions. There is also a view that the YST
component seems to inﬂuence the poor prognosis more so than the
endometrioid component.
It is difﬁcult to decide the treatment and determine the therapeutic
target lesion for this tumor. Cisplatin-based chemotherapy was used as
an adjuvant treatment in early reports (Nogales et al., 1996), and BEPnd multiple residual tumors disappeared after six courses of DC chemotherapy.
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with Carboplatin (Kamoi et al., 2002) were given in the subsequent re-
ports. In a recent report, Taxane and Carboplatin combination therapy
after BEP chemotherapy was used (Hong et al., 2010). However, the ef-
fects of these treatments were different in each case, and there is no
consensus about the effective therapy for this tumor.
Although YST associated with endometrioid adenocarcinoma is an
extremely rare tumor, the recognition of this histological subtype is im-
portant in differential diagnosis, because this tumor is greatly different
from pure YST in terms of the response to chemotherapy or the postop-
erative clinical course.
Despite our patient having residual lesions after operation, the
high serum level of AFP declined to normal and the target lesionsFig. 3. Histopathological and immunohistochemical ﬁndings. The histopathological studies sh
adenocarcinoma (B-1). The YST componentwas positive for AFP (A-2), but negative for CK7 (A-
for AFP (B-2), but positive for CK7 (B-3) and EMA (B-4).reduced signiﬁcantly after DC chemotherapy. Compared to previ-
ous reports, the response to chemotherapy and the clinical out-
come are extremely good in our case. A combination of Taxane
and Platinum has been suggested as the standard chemotherapy
for not only endometrioid adenocarcinoma but also YST in preg-
nancy (Amant et al., 2009), and consequently it might be effective
for both the YST and the endometrioid components. However,
this treatment had a poor response in another past case (Hong
et al., 2010). We could not determine the reason for her good prog-
nosis, but plan to follow this patient carefully considering the clin-
icopathological features of this tumor. Although the number of
cases is limited, the immediate establishment of treatment for
this rare tumor is desired.owed two different histological types, YST (A-1) and poorly differentiated endometrioid
3) and EMA (A-4). In contrast, the endometrioid adenocarcinoma componentwas negative
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